Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10271	URMC-099
BP10271	URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM).
BP10171	Urolithin A
BP10171	Urolithin A is a secondary metabolite of ellagic acid, a polyphenolic antioxidant, that has antiproliferative, anti-inflammatory, and anti-oxidant properties.
BP10715	Urolithin C
BP10715	Urolithin C is a gut metabolite of ellagic acid. Urolithin C induces apoptosis in PC12 cells through a mitochondria-mediated pathway.
BP10193	Vadimezan
BP10193	Vadimezan is a fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.
BP10823	Valepotriate
BP10823	Valepotriate fraction can have sedative effects and affect behavioral parameters related to recognition memory. Valepotriates, a new class of cytotoxic and antitumor agents, they are very potent cytotoxic agents for the HTC hepatoma cells. Valepotriates may have a potential anxiolytic effect on the psychic symptoms of anxiety.
BP10925	Valinomycin
BP10925	Valinomycin is a cyclic depsipeptide antibiotic and a potassium-specific ionophore.Valinomycin induces PINK1 activation and promotes Parkin phosphorylation at Ser65.
BP10525	VEGFR-2-IN-5
BP10525	UNC0064-12 is a patent compound in WO2013055780A1, multikinase inhibitor and has a -NH2 terminal linker for further synthesis.
BP10306	Venetoclax
BP10306	ABT-199 is a selective inhibitor of Bcl-2 (Ki < 0.010 nM), binding over 3 orders of magnitude less avidly to Bcl-xL, and Bcl-W (Kis = 48 and 245 nM, respectively).
BP10345	Verteporfin
BP10345	Verteporfin, a benzoporphyrin derivative monoacid ring A, can inhibit the activity of YAP.
BP10267	Vesatolimod
BP10267	GS-9620 is an effective and specific orally active agonist of Toll-like receptor 7.
BP10956	Vincristine sulfate
BP10956	Vincristine binds irreversibly to microtubules (Ki: 85 nM) and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle.
BP10016	Vistusertib
BP10016	AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity.
BP10766	Voreloxin
BP10766	Voreloxin is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity. Phase 2.
BP10767	Voreloxin hydrochloride
BP10767	Voreloxin hydrochloride is a potent inhibitor of Topoisomerase II with broad-spectrum anti-tumor activity.
BP10595	Vorinostat
BP10595	Vorinostat is a pan-inhibitor of Histone Deacetylase with antineoplastic activity (IC50: ~10 nM).
BP10022	Vorolanib
BP10022	Vorolanib is an orally active VEGFR/PDGFR dual inhibitor.
BP10689	VR23
BP10689	VR23 is a potent proteasome inhibitor. Data shows IC50 =1 nM for trypsin-like proteasomes, IC50=50-100 nM for chymotrypsin-like proteasomes, and IC50=3 μM for caspase-like proteasomes.
BP10920	WAY-311677
BP10920	WAY-311677 has potential antiproliferative activity and is a FAK inhibitor.
BP10096	WAY-600
BP10096	WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308); selective for mTOR than PI3Kα (>100-fold) and PI3Kγ (>500-fold).
BP10409	WEHI-345
BP10409	WEHI-345 is a potent and selective RIPK2 inhibitor which shows NOD signalling events yet prevents inflammatory cytokine production.